{"id":32498,"date":"2025-10-28T12:38:20","date_gmt":"2025-10-28T12:38:20","guid":{"rendered":"https:\/\/www.tabukpharmaceuticals.com\/?p=32498"},"modified":"2026-06-10T12:56:45","modified_gmt":"2026-06-10T12:56:45","slug":"tabuk-pharma-and-althera-laboratories-announce-strategic-licensing-and-supply-agreement-for-advanced-type-2-diabetes-therapy-in-mena","status":"publish","type":"post","link":"https:\/\/www.tabukpharmaceuticals.com\/ar\/tabuk-pharma-and-althera-laboratories-announce-strategic-licensing-and-supply-agreement-for-advanced-type-2-diabetes-therapy-in-mena\/","title":{"rendered":"Tabuk Pharma and Althera Laboratories Announce Strategic Licensing and Supply Agreement for Advanced Type 2 Diabetes Therapy in MENA"},"content":{"rendered":"<p>Tabuk Pharma has entered into a strategic partnership with Althera Laboratories to introduce an innovative treatment for type 2 diabetes across the MENA region.<\/p>\n<p>This collaboration reinforces Tabuk Pharma\u2019s commitment to expanding value-added therapeutic solutions and enhancing healthcare quality, in alignment with Saudi Vision 2030 and its ambition to advance the pharmaceutical sector and meet the region\u2019s evolving healthcare needs.<\/p>\n<p>For more information, please visit the full announcement.<br \/>\nhttps:\/\/www.linkedin.com\/posts\/tabuk-pharmaceutical-mfg-co_tabuk-pharmaceuticals-x-althera-laboratories-activity-7402386216521994240-tVME\/<\/p>","protected":false},"excerpt":{"rendered":"<p>Tabuk Pharma has entered into a strategic partnership with Althera Laboratories to introduce an innovative treatment for type 2 diabetes across the MENA region. This collaboration reinforces Tabuk Pharma\u2019s commitment to expanding value-added therapeutic solutions and enhancing healthcare quality, in alignment&#8230;<\/p>","protected":false},"author":1,"featured_media":32500,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61],"tags":[],"class_list":["post-32498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"_links":{"self":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/32498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/comments?post=32498"}],"version-history":[{"count":1,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/32498\/revisions"}],"predecessor-version":[{"id":32499,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/32498\/revisions\/32499"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media\/32500"}],"wp:attachment":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media?parent=32498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/categories?post=32498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/tags?post=32498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}